205 related articles for article (PubMed ID: 27890656)
21. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
22. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.
Chen AM; Zhang M; Wei D; Stueber D; Taratula O; Minko T; He H
Small; 2009 Dec; 5(23):2673-7. PubMed ID: 19780069
[No Abstract] [Full Text] [Related]
23. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.
Zhang P; Zhang P; Shi B; Zhou M; Jiang H; Zhang H; Pan X; Gao H; Sun H; Li Z
Cell Death Dis; 2014 Jan; 5(1):e991. PubMed ID: 24407244
[TBL] [Abstract][Full Text] [Related]
24. A mesoporous silica nanoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy.
Li X; Chen Y; Wang M; Ma Y; Xia W; Gu H
Biomaterials; 2013 Jan; 34(4):1391-401. PubMed ID: 23164421
[TBL] [Abstract][Full Text] [Related]
25. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
Talekar M; Ouyang Q; Goldberg MS; Amiji MM
Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
[TBL] [Abstract][Full Text] [Related]
26. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
27. Mesoporous Silica Nanoparticles as Carriers for Intracellular Delivery of Nucleic Acids and Subsequent Therapeutic Applications.
Cha W; Fan R; Miao Y; Zhou Y; Qin C; Shan X; Wan X; Li J
Molecules; 2017 May; 22(5):. PubMed ID: 28492505
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer.
Bao X; Zhao S; Liu T; Liu Y; Liu Y; Yang X
J Histochem Cytochem; 2013 Mar; 61(3):206-17. PubMed ID: 23292799
[TBL] [Abstract][Full Text] [Related]
29. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
30. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
Bahar E; Kim JY; Kim HS; Yoon H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076245
[TBL] [Abstract][Full Text] [Related]
31. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-219-5p inhibits the proliferation, migration, and invasion of epithelial ovarian cancer cells by targeting the Twist/Wnt/β-catenin signaling pathway.
Wei C; Zhang X; He S; Liu B; Han H; Sun X
Gene; 2017 Dec; 637():25-32. PubMed ID: 28890378
[TBL] [Abstract][Full Text] [Related]
33. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
Shi XL; Li Y; Zhao LM; Su LW; Ding G
Colloids Surf B Biointerfaces; 2019 Jan; 173():599-606. PubMed ID: 30352381
[TBL] [Abstract][Full Text] [Related]
34. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
35. siRNA in ovarian cancer - Delivery strategies and targets for therapy.
van den Brand D; Mertens V; Massuger LFAG; Brock R
J Control Release; 2018 Aug; 283():45-58. PubMed ID: 29777795
[TBL] [Abstract][Full Text] [Related]
36. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
[TBL] [Abstract][Full Text] [Related]
37. The packaging of siRNA within the mesoporous structure of silica nanoparticles.
Li X; Xie QR; Zhang J; Xia W; Gu H
Biomaterials; 2011 Dec; 32(35):9546-56. PubMed ID: 21906804
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of matrix metalloproteinase 9 by small interfering RNA inhibits the tumor growth of ovarian epithelial carcinoma in vitro and in vivo.
Guo F; Tian J; Cui M; Fang M; Yang L
Mol Med Rep; 2015 Jul; 12(1):753-9. PubMed ID: 25738807
[TBL] [Abstract][Full Text] [Related]
39. [Effect of S1PR2 inhibition on epithelial ovarian cancer SKOV3 cell proliferation in vitro and in vivo].
Dai L; Liu YX; Xie L; Di W
Zhonghua Fu Chan Ke Za Zhi; 2018 Feb; 53(2):106-110. PubMed ID: 29534379
[No Abstract] [Full Text] [Related]
40. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
